Author/Authors :
Moghoofei Mohsen Department of Microbiology - Faculty of Medicine - Kermanshah University of Medical Sciences - Kermanshah, Iran , Babaei Farhad Department of Microbiology - Faculty of Medicine - Kermanshah University of Medical Sciences - Kermanshah, Iran , Nouri Majid Golestan Hospital Research Center - Tehran, Iran , Kamakifar Parvin Department of Microbiology - Faculty of Medicine - Zanjan University of Medical Sciences - Zanjan, Iran , Khodabandehlou Niloofar Department of Internal Medicine - Faculty of Medicine - Iran University of Medical Sciences - Tehran, Iran , Sadri Nahand Javid Department of Medical Virology - Faculty of Medicine - Iran University of Medical Sciences - Tehran, Iran , Tavakoli Ahmad Department of Medical Virology - Faculty of Medicine - Iran University of Medical Sciences - Tehran, Iran , Norooznezhad Fatemeh Infectious Diseases Research Center - Kermanshah University of Medical Sciences - Kermanshah, Iran , Sorayyayi Saba Department of Clinical Biochemistry - Faculty of Medicine - Ardabil University of Medical Sciences - Ardabil, Iran , Mostafaei Shayan Medical Biology Research Center - Institute of Health and Technology - Kermanshah University of Medical Sciences - Kermanshah, Iran
Abstract :
Human parvovirus B19 (B19V) can cause anemia in some patients, including those with compromised immunity
system. There are a few studies on molecular epidemiology of B19V and its association with anemia in Iran. Therefore, the aim of this
study was to determine the B19V DNA, IgM, IgG, genotyping, and viral load in HIV patients in different groups of pregnant women,
general population, injection drug users (IDU), and Elite controllers. Also, the possible association of B19V with anemia was studied.
Methods: In this case-control study, B19V DNA, anti-B19V IgM, anti-B19V IgG, viral load, and hemoglobin level were assessed in
113 HIV positive patients and 72 healthy controls. Also, CD4+ T cell counts and HIV load were measured in the patients’ group. All
statistical analyses were done using STATA 14.2 software (Stata Corporation, College Station, Texas, USA). P value < 0.05 was
considered statistically significant.
Results: Among HIV patients, 19 (16.8%) cases had B19V DNA, 3 (2.7%) had B19V IgM, and 7 (6.2%) had B19V IgG. In control
group, the prevalence of B19V DNA, IgM, and IgG was 6 (8.33%), 7(9.7%), and 19 (26.4%), respectively. In subpopulations based on
transmission routes, general population had the highest B19V IgG and DNA positivity prevalence and viral load level. There was no
significant association between B19V antibodies and DNA with anemia.
Conclusion: The results demonstrated that B19V infection cannot be considered as a high-risk factor for anemia in adult HIV
patients. However, further studies are needed to determine the exact role of B19V infection in HIV patients
Keywords :
Iran , Human immunodeficiency virus , Parvovirus B19 , Anemia
